Su Yaxin, Zhang Lei, Zhou Yao, Ding Lei, Li Li, Wang Zhongcheng
Department of Pathophysiology, School of Basic Medical Sciences, Xuzhou Medical University, Tongshan Road No. 209, Xuzhou, 221004, China.
J Physiol Biochem. 2022 Feb;78(1):1-8. doi: 10.1007/s13105-021-00841-w. Epub 2021 Sep 2.
Stroke, also known as cerebral stroke or cerebrovascular accident, refers to acute ischemic or hemorrhagic encephalopathy caused by a disturbance to cerebral blood flow. Ischemic stroke is the most common type of cerebral stroke, accounting for approximately 80% of the total incidence of clinical stroke. High morbidity, disability, and mortality rates place heavy burdens on the families of patients and society. An increasing number of studies have shown that histone modification plays an important role in the pathogenesis of ischemic stroke, but most studies on histone modification focus on acetylation, and studies on the role of histone methylation in the pathogenesis of ischemic stroke are limited. Here, we review the role of histone methylation and related histone methyltransferase (HMT) inhibitors in the pathogenesis of ischemic stroke and related HMT inhibitors in the treatment of ischemic stroke, which may open up a new avenue to the study of ischemic stroke.
中风，也称为脑卒或脑血管意外，是指由于脑血流紊乱引起的急性缺血性或出血性脑病。缺血性中风是最常见的脑卒类型，约占临床脑卒中总发病率的80%。高发病率、致残率和死亡率给患者家庭和社会带来了沉重负担。越来越多的研究表明，组蛋白修饰在缺血性中风的发病机制中起重要作用，但大多数关于组蛋白修饰的研究集中在乙酰化上，而关于组蛋白甲基化在缺血性中风发病机制中的作用的研究有限。在此，我们综述组蛋白甲基化及相关组蛋白甲基转移酶（HMT）抑制剂在缺血性中风发病机制中的作用以及相关HMT抑制剂在缺血性中风治疗中的作用，这可能为缺血性中风的研究开辟一条新途径。
